CN107137771A - 一种纳米磷酸钙骨水泥及其制备方法 - Google Patents
一种纳米磷酸钙骨水泥及其制备方法 Download PDFInfo
- Publication number
- CN107137771A CN107137771A CN201710299348.9A CN201710299348A CN107137771A CN 107137771 A CN107137771 A CN 107137771A CN 201710299348 A CN201710299348 A CN 201710299348A CN 107137771 A CN107137771 A CN 107137771A
- Authority
- CN
- China
- Prior art keywords
- bone cement
- calcium phosphate
- nano
- water
- nanometer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002639 bone cement Substances 0.000 title claims abstract description 105
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 45
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000002086 nanomaterial Substances 0.000 claims abstract description 42
- 239000000843 powder Substances 0.000 claims abstract description 36
- 235000011010 calcium phosphates Nutrition 0.000 claims abstract description 29
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 29
- 239000000463 material Substances 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims description 37
- 239000007790 solid phase Substances 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 27
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 claims description 24
- 229920001661 Chitosan Polymers 0.000 claims description 23
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 22
- 210000000988 bone and bone Anatomy 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000007864 aqueous solution Substances 0.000 claims description 16
- DQMUQFUTDWISTM-UHFFFAOYSA-N O.[O-2].[Fe+2].[Fe+2].[O-2] Chemical class O.[O-2].[Fe+2].[Fe+2].[O-2] DQMUQFUTDWISTM-UHFFFAOYSA-N 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 8
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 8
- 239000000084 colloidal system Substances 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229910014771 Ca4(PO4)2O Inorganic materials 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
- 230000002188 osteogenic effect Effects 0.000 abstract description 4
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 3
- 239000002184 metal Substances 0.000 abstract description 3
- 239000011159 matrix material Substances 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000001354 calcination Methods 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 238000003746 solid phase reaction Methods 0.000 description 6
- 238000010671 solid-state reaction Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 150000003893 lactate salts Chemical class 0.000 description 4
- 239000006193 liquid solution Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940102709 ferumoxytol Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000005543 nano-size silicon particle Substances 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960005346 succimer Drugs 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Materials For Medical Uses (AREA)
Abstract
一种纳米磷酸钙骨水泥及其制备方法,由水溶性纳米材料添加到磷酸钙骨水泥中,调拌均匀后自固化制得。本发明选择生物相容性良好的金属纳米材料与骨水泥基质粉体混合制备纳米骨水泥,不仅使材料具有良好的机械性能,而且具有增强的成骨活性。还可以通过调节加入纳米材料的种类和数量对纳米骨水泥的性能进行调节,如通过添加磁性纳米材料来赋予骨水泥以磁性,通过在一定范围内增加纳米材料添加量来增强骨水泥的强度。本发明的纳米骨水泥材料制备方法工业简单,可操作性强,且更能满足临床使用需要,具备推广价值。
Description
技术领域
本发明属于生物医用无机材料技术领域,具体涉及一种纳米磷酸钙骨水泥及其制备方法。
背景技术
口腔颌面部先天畸形、创伤、肿瘤、炎症等所致的颌骨缺损不仅造成颜面畸形,还可引起语言、咀嚼、呼吸等口腔功能障碍,给患者生理、心理等方面带来许多不良影响。因此,颌骨缺损一直是临床治疗的重点和难点。骨移植是最常用的治疗方法,植骨材料包括自体骨、异体骨、异种骨和人工骨等。其中自体骨被认为是治疗骨缺损的“金标准”。但自体骨和异体骨来源有限,异种骨又存在抗原性强等问题,使其临床应用受到限制。骨组织工程技术以人工骨修复骨缺损,具有损伤小、无抗原性或抗原性甚微,可以准确重建缺损骨的形态等优点。
磷酸钙骨水泥是20世纪90年代初研制成功的一种具有生物活性的自固型、非陶瓷羟基磷灰石类人工骨材料。其生物相容性好,在固化结晶过程中不产热,可任意塑形和逐渐降解,并可诱导骨组织长入,符合临床骨缺损修复的需要。磷酸钙骨水泥也被用作生长因子的缓释载体和构建组织工程骨。但其存在缺点,如凝固速度慢,强度低、力学性能差,脆性大且承受载荷的能力差,成骨速度慢,大大限制了应用。
以纳米材料对磷酸钙骨水泥进行改良是一条可行之路。目前开发的纳米磷酸钙骨水泥主要集中在无机非金属类纳米材料,如纳米二氧化硅、纳米壳聚糖、纳米晶体纤维素等。这些无机非金属类纳米材料的添加使磷酸钙骨水泥中的孔隙和裂纹减少,颗粒尺寸减少,同时纳米材料可以发挥补强增韧的作用,从而提高了磷酸钙骨水泥的强度。但是对其成骨性能方面,还需要通过添加药物或者生长因子的方式进行进一步改良。基于此,开发可以同时改良物理机械性能又可增强成骨活性的纳米磷酸钙骨水泥亟待解决。
金属纳米材料在生物医学领域有着广泛的应用,其具有增强添加物和活性药物的双重功能。比如具有超顺磁性的γ三氧化二铁,作为磁共振造影剂已通过FDA的认证。近年来,其也开始被添加入骨组织工程的支架材料中以提高支架的机械强度和生物活性。添加的铁元素随支架的降解而在局部逐步释放,可提高干细胞线粒体活性和成骨相关基因的表达。γ三氧化二铁赋予支架超顺磁性,可作为磁性标记的生长因子或干细胞的靶目标而实现定向作用。磁性支架在外加磁场的辅助下可固定于植入的骨缺损区,减少移位。纳米金具有良好的纳米表面效应、量子效应以及宏观量子隧道效应,它具有很多良好的化学特性,比如抗氧性和生物相容性,因此在生物医学领域极具应用潜力。
发明内容
解决的技术问题:本发明的目的是提供一种具有良好机械性能和成骨活性的磷酸钙骨水泥。 同时还提供该纳米骨水泥的制备方法。
技术方案:一种纳米磷酸钙骨水泥,是由水溶性纳米材料添加到磷酸钙骨水泥中,调拌均匀后自固化制得。
上述磷酸钙骨水泥为磷酸四钙[Ca4(PO4)2O]和无水磷酸氢钙[CaHPO4]体系;所述磷酸四钙颗粒尺寸范围为1μm~80μm;无水磷酸氢钙尺寸范围为0.4μm~3μm;磷酸四钙与无水磷酸氢钙的摩尔比为1:1-1:3,混合后得到磷酸钙骨水泥的粉体。
上述水溶性纳米材料为表面修饰的纳米金、纳米γ三氧化二铁、纳米α三氧化二铁,及上述材料稳定的单分散性胶体溶液或干燥后得到的固体颗粒。
上述表面修饰物为二巯丁二酸(DMSA)、聚葡萄糖山梨醇羧甲醚(PSC)、聚乙二醇(PEG)或柠檬酸,尺寸为5 nm~100nm。
纳米磷酸钙骨水泥的制备方法,步骤为:准备固化液:所述固化液为水、血液、水溶性纳米材料的水溶液或5-20 wt.%的壳聚糖水溶液;制备固相:按照水溶性纳米材料占磷酸钙骨水泥质量不超过6%混合,制得纳米骨水泥固相;以水溶性纳米材料的水溶液为骨水泥固化液时,直接以磷酸四钙和无水磷酸氢钙混合物为纳米骨水泥固相;按照纳米骨水泥固相/液相质量比例2:1-4:1,将固化液加入纳米骨水泥固相中,调拌均匀;置于37℃100% 湿度环境中固化4h-7d。
上述固化液为0.5-50mg/mL水溶性纳米材料的水溶液或5-20 wt.%壳聚糖水溶液。
上述壳聚糖水溶液为壳聚糖乳酸盐或者壳聚糖马来酸盐的水溶液。
在添加固体水溶性纳米材料时,先将固体水溶性纳米材料均匀分散在磷酸钙骨水泥粉体中,再与固化液调拌均匀并固化。
有益效果:本发明选择生物相容性良好的金属纳米材料与骨水泥基质粉体混合制备纳米骨水泥,不仅使材料具有良好的机械性能,而且具有增强的成骨活性。还可以通过调节加入纳米材料的种类和数量对纳米骨水泥的性能进行调节,如通过添加磁性纳米材料来赋予骨水泥以磁性,通过在一定范围内增加纳米材料添加量来增强骨水泥的强度。本发明的纳米骨水泥材料制备方法工业简单,可操作性强,且更能满足临床使用需要,具备推广价值。
附图说明
图1为实施例4和对比例(5#)所制备纳米骨水泥的弯曲强度图;
图2 为实施例3(4#)所制备纳米骨水泥的扫描电镜图;
图3为实施例4-6(6#、7#、8#)和对比例(5#)所制备的纳米骨水泥的磁滞回线图;
图4为实施例4-6(6#、7#、8#)和对比例(5#)所制备纳米骨水泥的X线衍射图谱;
图5为实施例1-2和对比例(1#)所制备纳米骨水泥的细胞增殖结果图;
图6为实施例1-2和对比例(1#)所制备纳米骨水泥的碱性磷酸酶活性检测结果图;
图7为实施例1-2和对比例(1#)所制备纳米骨水泥的钙结节形成定量检测结果图。
具体实施方式
下面的实施例可使本专业技术人员更全面地理解本发明,但不以任何方式限制本发明。
实施例1(2#)
本实施例的纳米骨水泥固相为摩尔比为1:3的磷酸四钙和无水磷酸氢钙混合物,粉液组分组成为:2份纳米骨水泥固相粉体,1份PSC包裹的纳米γ三氧化二铁胶体溶液(RosnerMH, Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert RevHematol. 2011 Aug;4(4):399-406.)。
其中磷酸四钙的制备方法如下:用固态反应法合成磷酸四钙粉末,等摩尔量的无水磷酸氢钙和碳酸钙在1500℃炉中煅烧6小时,升温速度25°C/min,煅烧后冷却,在球磨机中研磨至平均粒径为5μm。无水磷酸钙的平均粒径为1μm。
其中纳米材料为PSC包裹的纳米γ-三氧化二铁胶体溶液,平均粒径9nm,并以其为骨水泥固化液。
本实施例的纳米骨水泥采用如下步骤制备:
(1)制备浓度为24mg/mL的PSC包裹的纳米γ三氧化二铁胶体溶液作为固化液;
(2)按照粉液质量比2:1取磷酸钙纳米骨水泥固相粉体2份,取纳米γ三氧化二铁胶体溶液1份,将溶液加入固相中调拌均匀,置于37℃100% 湿度环境中固化24h-7d。
实施例2(3#)
本实施例的纳米骨水泥的制备步骤与实施例1相同,区别在于纳米材料为DMSA包裹的纳米α三氧化二铁胶体溶液,浓度为2.55 mg/mL,具体的实施例内容为:本实施例的纳米骨水泥材料,是由以下粉液组分组成:2份摩尔比为1:3的磷酸四钙和无水磷酸氢钙混合物,1份DMSA包裹的纳米α三氧化二铁胶体溶液(Sun J, Su Y, Wang C, Gu N. Theinvestigation of frequency response for the magnetic nanoparticulate assemblyinduced by time-varied magnetic field. Nanoscale Res Lett. 2011 Jul 14;6:453.)。
其中磷酸四钙的制备方法如下:用固态反应法合成磷酸四钙粉末,等摩尔量的无水磷酸氢钙和碳酸钙在1500℃炉中煅烧6小时,升温速度25°C/min,煅烧后冷却,在球磨机中研磨至平均粒径为5μm。无水磷酸钙的平均粒径为1μm。
其中纳米材料为DMSA包裹的纳米α三氧化二铁胶体溶液,平均粒径50纳米,并以其为骨水泥固化液。
本实施例的纳米骨水泥采用如下步骤制备:
(1)制备浓度为2.55mg/mL的DMSA包裹的纳米α三氧化二铁胶体溶液作为固化液;
(2)按照粉液质量比比2:1取磷酸钙纳米骨水泥固相粉体2份,取DMSA包裹的纳米α三氧化二铁胶体溶液1份,将溶液加入固相中调拌均匀,置于37℃100% 湿度环境中固化24h-7d。
实施例3(4#)
本实施例的纳米骨水泥的制备步骤与实施例1相同,区别在于纳米材料为柠檬酸包裹的纳米金胶体溶液,浓度为0.5mg/mL,具体的实施例内容为:本实施例的纳米骨水泥材料,是由以下粉液组分组成:2份摩尔比为1:3的磷酸四钙和无水磷酸氢钙混合物,1份柠檬酸包裹的纳米金胶体溶液(Wang P, Sun J, Lou Z, Fan F, Hu K, Sun Y, Gu N. Assembly-Induced Thermogenesis of Gold Nanoparticles in the Presence of AlternatingMagnetic Field for Controllable Drug Release of Hydrogel. Adv Mater. 2016Dec;28(48):10801-10808.)。
其中磷酸四钙的制备方法如下:用固态反应法合成磷酸四钙粉末,等摩尔量的无水磷酸氢钙和碳酸钙在1500℃炉中煅烧6小时,升温速度25°C/min,煅烧后冷却,在球磨机中研磨至平均粒径为5μm。无水磷酸钙的平均粒径为1μm。
其中纳米材料为柠檬酸包裹的纳米金胶体溶液,平均粒径18nm,并以其为骨水泥固化液。
本实施例的纳米骨水泥采用如下步骤制备:
(1)制备浓度为0.5mg/mL的柠檬酸钠包裹的纳米金胶体溶液作为固化液;
(2)按照粉液质量比2:1取磷酸钙纳米骨水泥固相粉体2份,取柠檬酸钠包裹的纳米金胶体溶液1份,将溶液加入固相中调拌均匀,置于37℃100% 湿度环境中固化24h-7d。
实施例4
本实施例的纳米骨水泥材料,是由以下重量份的组分组成:100份摩尔比为1:3的磷酸四钙和无水磷酸氢钙混合物,PSC包裹的纳米γ三氧化二铁为1份(6#)。
其中磷酸四钙的制备方法如下:用固态反应法合成磷酸四钙粉末,等摩尔量的无水磷酸氢钙和碳酸钙在1500℃炉中煅烧6小时,升温速度25℃/min,煅烧后冷却,在球磨机中研磨至平均粒径为5μm。无水磷酸钙的平均粒径为1μm。
其中纳米材料为PSC包裹的纳米γ三氧化二铁颗粒,由其稳定胶体溶液经喷雾干燥法获得。
骨水泥固化液的制备,称取0.5克乳酸化壳聚糖,溶解于10mL水中,制备得到浓度为5wt.%乳酸壳聚糖水溶液。
本实施例的纳米骨水泥采用如下步骤制备:
(1)制备浓度为5wt.%乳酸壳聚糖溶液的骨水泥固化液;
(2)按照取磷酸钙纳米骨水泥固相粉体100份,取PSC包裹的纳米γ三氧化二铁颗粒0-6份,将纳米颗粒添加入骨水泥粉体并调拌均匀,得到纳米骨水泥固相粉体;
(3)以粉液质量比2:1,将5wt.%乳酸壳聚糖溶液加入固相中调拌均匀,并置于37℃100%湿度环境中固化24h-7d。
实施例5
本实施例的纳米骨水泥材料,是由以下重量份的组分组成:100份摩尔比为1:3的磷酸四钙和无水磷酸氢钙混合物,PSC包裹的纳米γ三氧化二铁为3份(7#)。
其中磷酸四钙的制备方法如下:用固态反应法合成磷酸四钙粉末,等摩尔量的无水磷酸氢钙和碳酸钙在1500℃炉中煅烧6小时,升温速度25℃/min,煅烧后冷却,在球磨机中研磨至平均粒径为5μm。无水磷酸钙的平均粒径为1μm。
其中纳米材料为PSC包裹的纳米γ三氧化二铁颗粒,由其稳定胶体溶液经喷雾干燥法获得。
骨水泥固化液的制备,称取0.5克乳酸化壳聚糖,溶解于10mL水中,制备得到浓度为5wt.%乳酸壳聚糖水溶液。
本实施例的纳米骨水泥采用如下步骤制备:
(1)制备浓度为5wt.%乳酸壳聚糖溶液的骨水泥固化液;
(2)按照取磷酸钙纳米骨水泥固相粉体100份,取PSC包裹的纳米γ三氧化二铁颗粒0-6份,将纳米颗粒添加入骨水泥粉体并调拌均匀,得到纳米骨水泥固相粉体;
(3)以粉液质量比2:1,将5wt.%乳酸壳聚糖溶液加入固相中调拌均匀,并置于37℃100%湿度环境中固化24h-7d。
实施例6
本实施例的纳米骨水泥材料,是由以下重量份的组分组成:100份摩尔比为1:3的磷酸四钙和无水磷酸氢钙混合物,PSC包裹的纳米γ三氧化二铁为6份(8#)。
其中磷酸四钙的制备方法如下:用固态反应法合成磷酸四钙粉末,等摩尔量的无水磷酸氢钙和碳酸钙在1500℃炉中煅烧6小时,升温速度25℃/min,煅烧后冷却,在球磨机中研磨至平均粒径为5μm。无水磷酸钙的平均粒径为1μm。
其中纳米材料为PSC包裹的纳米γ三氧化二铁颗粒,由其稳定胶体溶液经喷雾干燥法获得。
骨水泥固化液的制备,称取0.5克乳酸化壳聚糖,溶解于10mL水中,制备得到浓度为5wt.%乳酸壳聚糖水溶液。
本实施例的纳米骨水泥采用如下步骤制备:
(1)制备浓度为5wt.%乳酸壳聚糖溶液的骨水泥固化液;
(2)按照取磷酸钙纳米骨水泥固相粉体100份,取PSC包裹的纳米γ三氧化二铁颗粒0-6份,将纳米颗粒添加入骨水泥粉体并调拌均匀,得到纳米骨水泥固相粉体;
(3)以粉液质量比2:1,将5wt.%乳酸壳聚糖溶液加入固相中调拌均匀,并置于37℃100%湿度环境中固化24h-7d。
对比例
本实施例的骨水泥材料与实施例1基本相同,区别在于以水(1#)或5wt.%乳酸壳聚糖溶液(5#)为骨水泥固化液。所以本对比例中骨水泥未添加纳米材料。
检测例
将实施例1-4和对比例进行如下性能试验:
1. 抗压强度和弹性模量的测定
取固相粉末与液相搅拌均匀后,将样品制成3×4×20mm的长条状试样,将其在相对湿度 100%的 37℃恒温箱内养护 72h,使用万能材料测试仪Instron 5500nR测试其抗压强度,加载速度1 mm/min,跨距为20mm。每组选取5个无损试样,测试其平均值。具体的测定结果如图1所示:纳米骨水泥的弯曲强度。可以看出,不添加纳米材料的骨水泥的弯曲强度为4MPa左右,但是本发明的纳米骨水泥材料中掺入了纳米铁,材料的力学性能得到了提高。当掺入比例为3wt.%左右,材料的抗压强度达到8MPa左右。
2. 磁性测试
将材料制成直径 6毫米,厚1毫米的圆片,使用振动样品磁强计(Lake shore7410)检测其磁性。磁滞回线可以看出,材料出现了超顺磁性,且磁性强度随纳米材料的添加量而增加(图3)。超顺磁性能提高材料的磁生热能力。
3. 材料的晶相组成。当磷酸四钙与无水磷酸钙的摩尔比为1:1时,固相粉体和液相调和后会发生反应生成羟基磷灰石[Ca5(PO4)3OH]。而当磷酸四钙与无水磷酸钙的摩尔比小于1时,会生成缺钙磷灰石。从材料的X射线衍射图谱可见,纳米材料的加入对骨水泥晶相形成没有影响(图4)。
4. 细胞增殖性能检测
将材料烘干消毒,加入培养基中,37℃预孵育后,进行细胞实验。取复苏后生长旺盛的人牙髓干细胞接种(密度为6×103个/mL)48孔培养板内。细胞培养1d、4d、7d和14d后,加入含10%CCK-8的培养基,37℃下继续培养2h,终止培养,吸取液体至96孔板内,用酶标仪在450nm波长下读取吸光度值,记录结果。做3个平行样,具体测定结果如图5。从图5可以看出,纳米骨水泥的细胞相容性良好。
5. 细胞分化性能检测(碱性磷酸酶活性检测)
用吸管吸掉96孔板内的培养液,用PBS冲洗3遍,加入含25mmol/L二乙醇胺,1mmol/L氯化镁和6.7mmol/L PNPP的反应液。每孔150μL在37℃避光放置30min,然后加0.1mol/L氢氧化钠100μL终止反应,用酶标仪于405nm波长下测定OD值。样品OD值在ALP标准曲线上读取酶活性值。将测得的OD值除以同批细胞的蛋白含量均值进行统计分析,以消除细胞总蛋白量不同对ALP值的影响。具体测定结果如图6。从图6可以看出,纳米骨水泥的碱性磷酸酶活性增高。
6. 钙化结节染色和定量检测
用茜素红法对钙化结节进行染色,吸弃原培养基,用1×PBS冲洗,用10%福尔马林在室温固定30min,再用1×PBS冲洗一次,用2%茜素红染料室温避光染色45min。用1×PBS冲洗2次。然后用10%的氯化十六烷基吡啶溶解后进行定量检测,溶解15min,用酶标仪在波长550nm读取吸光度值。具体测定结果如图7。从检测结果可以看出,纳米骨水泥的钙化结节形成量显著增加。
Claims (8)
1.一种纳米磷酸钙骨水泥,其特征在于是由水溶性纳米材料添加到磷酸钙骨水泥中,调拌均匀后自固化制得。
2.根据权利要求1所述的纳米磷酸钙骨水泥,其特征在于所述磷酸钙骨水泥为磷酸四钙[Ca4(PO4)2O]和无水磷酸氢钙[CaHPO4]体系;所述磷酸四钙颗粒尺寸范围为1μm~80μm;无水磷酸氢钙尺寸范围为0.4μm~3μm;磷酸四钙与无水磷酸氢钙的摩尔比为1:1-1:3,混合后得到磷酸钙骨水泥的粉体。
3.根据权利要求1所述的纳米磷酸钙骨水泥,其特征在于所述水溶性纳米材料为表面修饰的纳米金、纳米γ三氧化二铁、纳米α三氧化二铁,及上述材料稳定的单分散性胶体溶液或干燥后得到的固体颗粒。
4.根据权利要求3所述的纳米磷酸钙骨水泥,其特征在于所述表面修饰物为二巯丁二酸、聚葡萄糖山梨醇羧甲醚、聚乙二醇或柠檬酸,尺寸为5 nm~100nm。
5.权利要求1~4任一所述纳米磷酸钙骨水泥的制备方法,其特征在于步骤为:
(1)准备固化液:所述固化液为水、血液、水溶性纳米材料的水溶液或5-20 wt.%的壳聚糖水溶液;
(2)制备固相:按照水溶性纳米材料占磷酸钙骨水泥质量不超过6%混合,制得纳米骨水泥固相;
(3)以水溶性纳米材料的水溶液为骨水泥固化液时,直接以磷酸四钙和无水磷酸氢钙混合物为纳米骨水泥固相;
(4)按照纳米骨水泥固相/液相质量比例2:1-4:1,将固化液加入纳米骨水泥固相中,调拌均匀;
(5)置于37℃100% 湿度环境中固化4h-7d。
6.根据权利要求5所述一种纳米磷酸钙骨水泥的制备方法,其特征在于所述的固化液为0.5-50mg/mL水溶性纳米材料的水溶液或5-20 wt.%壳聚糖水溶液。
7.根据权利要求1所述一种纳米磷酸钙骨水泥的制备方法,其特征在于所述壳聚糖水溶液为壳聚糖乳酸盐或者壳聚糖马来酸盐的水溶液。
8.根据权利要求1所述一种纳米磷酸钙骨水泥的制备方法,其特征在于在添加固体水溶性纳米材料时,先将固体水溶性纳米材料均匀分散在磷酸钙骨水泥粉体中,再与固化液调拌均匀并固化。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710299348.9A CN107137771B (zh) | 2017-05-02 | 2017-05-02 | 一种纳米磷酸钙骨水泥及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710299348.9A CN107137771B (zh) | 2017-05-02 | 2017-05-02 | 一种纳米磷酸钙骨水泥及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107137771A true CN107137771A (zh) | 2017-09-08 |
CN107137771B CN107137771B (zh) | 2020-02-07 |
Family
ID=59774918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710299348.9A Expired - Fee Related CN107137771B (zh) | 2017-05-02 | 2017-05-02 | 一种纳米磷酸钙骨水泥及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107137771B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107670102A (zh) * | 2017-11-19 | 2018-02-09 | 赵亮 | 一种募集内源性细胞的骨生物复合材料和制备方法及应用 |
CN108949893A (zh) * | 2017-08-04 | 2018-12-07 | 璧典寒 | 一种骨生物功能分析细胞培养板 |
CN113750289A (zh) * | 2021-10-20 | 2021-12-07 | 香港大学深圳医院 | 基于磷酸钙的有机-无机复合生物活性材料及其制备方法 |
WO2022134163A1 (zh) * | 2020-12-25 | 2022-06-30 | 光华临港工程应用技术研发(上海)有限公司 | 磷酸钙基水泥灌封材料及其制造方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101352584A (zh) * | 2007-07-26 | 2009-01-28 | 瑞安大药厂股份有限公司 | 具有生物可分解性的骨水泥及其制备方法 |
CN102049066A (zh) * | 2009-11-10 | 2011-05-11 | 中国医学科学院基础医学研究所 | 一种磁性复合材料及其在骨组织再生和修复中的应用 |
CN102349930A (zh) * | 2011-11-01 | 2012-02-15 | 东南大学 | 具有抗氧化活性的氧化铁纳米粒水凝胶剂 |
CN105251012A (zh) * | 2015-08-11 | 2016-01-20 | 同济大学 | 纳米金包覆层状双氢氧化物复合材料及其制备和应用 |
-
2017
- 2017-05-02 CN CN201710299348.9A patent/CN107137771B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101352584A (zh) * | 2007-07-26 | 2009-01-28 | 瑞安大药厂股份有限公司 | 具有生物可分解性的骨水泥及其制备方法 |
CN102049066A (zh) * | 2009-11-10 | 2011-05-11 | 中国医学科学院基础医学研究所 | 一种磁性复合材料及其在骨组织再生和修复中的应用 |
CN102349930A (zh) * | 2011-11-01 | 2012-02-15 | 东南大学 | 具有抗氧化活性的氧化铁纳米粒水凝胶剂 |
CN105251012A (zh) * | 2015-08-11 | 2016-01-20 | 同济大学 | 纳米金包覆层状双氢氧化物复合材料及其制备和应用 |
Non-Patent Citations (3)
Title |
---|
CHANGQING YI等: "Gold Nanoparticles Promote Osteogenic", 《ACS NANO》 * |
QIWEI WANG等: "Response of MAPK pathway to iron oxide nanoparticles in vitro treatment promotes osteogenic differentiation of hBMSCs", 《BIOMATERIALS》 * |
马立新等: "自硬化磷酸钙骨水泥的微结构分析", 《硅酸盐通报》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108949893A (zh) * | 2017-08-04 | 2018-12-07 | 璧典寒 | 一种骨生物功能分析细胞培养板 |
CN107670102A (zh) * | 2017-11-19 | 2018-02-09 | 赵亮 | 一种募集内源性细胞的骨生物复合材料和制备方法及应用 |
WO2022134163A1 (zh) * | 2020-12-25 | 2022-06-30 | 光华临港工程应用技术研发(上海)有限公司 | 磷酸钙基水泥灌封材料及其制造方法 |
CN113750289A (zh) * | 2021-10-20 | 2021-12-07 | 香港大学深圳医院 | 基于磷酸钙的有机-无机复合生物活性材料及其制备方法 |
WO2023065474A1 (zh) * | 2021-10-20 | 2023-04-27 | 香港大学深圳医院 | 基于磷酸钙的有机-无机复合生物活性材料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107137771B (zh) | 2020-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107137771A (zh) | 一种纳米磷酸钙骨水泥及其制备方法 | |
Xia et al. | Iron oxide nanoparticle-calcium phosphate cement enhanced the osteogenic activities of stem cells through WNT/β-catenin signaling | |
Dasgupta et al. | Zn-and Mg-doped hydroxyapatite nanoparticles for controlled release of protein | |
Perez et al. | Novel magnetic nanocomposite injectables: calcium phosphate cements impregnated with ultrafine magnetic nanoparticles for bone regeneration | |
Chen et al. | Regulatory synthesis and characterization of hydroxyapatite nanocrystals by a microwave-assisted hydrothermal method | |
Chen et al. | Europium-doped amorphous calcium phosphate porous nanospheres: preparation and application as luminescent drug carriers | |
Kumar et al. | Flower-like hydroxyapatite nanostructure obtained from eggshell: A candidate for biomedical applications | |
CN104288830B (zh) | 一种微纳米棒状生物活性玻璃及其制备方法与应用 | |
CN102826524B (zh) | 微波-超声法制备介孔羟基磷灰石纳米粒子及其应用 | |
Li et al. | Controllable synthesis of biomimetic hydroxyapatite nanorods with high osteogenic bioactivity | |
Sheikh et al. | Biomimetic matrix mediated room temperature synthesis and characterization of nano-hydroxyapatite towards targeted drug delivery | |
CN113307240B (zh) | 一种具有抗肿瘤活性的纳米羟基磷灰石粒子及其制备方法 | |
Dreanca et al. | Bioactive glass-biopolymers‑gold nanoparticle based composites for tissue engineering applications | |
CN110420357A (zh) | 适用于3d打印的载药改性介孔羟基磷灰石生物医用复合材料、制备方法及其应用 | |
US8246736B2 (en) | Tricalcium phosphate coarse particle compositions and methods for making the same | |
Lakrat et al. | Three-dimensional nano-hydroxyapatite sodium silicate glass composite scaffold for bone tissue engineering-A new fabrication process at a near-room temperature | |
TW200934461A (en) | Calcium silicate-based cements and manufacturing method thereof | |
Li et al. | Facile synthesis and characterization of novel rapid-setting spherical sub-micron bioactive glasses cements and their biocompatibility in vitro | |
CN1693415B (zh) | 近红外荧光量子点标记的羟基磷灰石及其制备方法和应用 | |
US11890392B2 (en) | Absorbable bone wax and preparation method thereof | |
Ghosh et al. | A succinct overview of hydroxyapatite based nanocomposite biomaterials: Fabrications, physicochemical properties and some relevant biomedical applications | |
Farag et al. | Dental pulp stem cell viability and osteogenic potential assessment of new Mg-phosphate magnetic bioceramic nanoparticles | |
Sha et al. | Physico-chemical and biological properties of novel Eu-doped carbonization modified tricalcium silicate composite bone cement | |
KR20160028070A (ko) | 자성 나노입자를 포함하는 고세포부착성 인산칼슘 골시멘트 조성물, 이의 제조방법 및 이의 제조를 위한 키트 | |
Saatci et al. | Synthesis and in vitro characterization of superparamagnetic γ-Fe2O3-containing 13–93 bioactive glasses for bone cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200207 |